Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vascular smooth muscle cell (VSMC) apoptosis accelerates atherosclerosis and promotes restenosis following vascular injury. The current study examined the effects of
cellular repressor of E1A-stimulated genes
(
CREG
), a novel glycoprotein inhibiting transcription activation, on the regulation of VSMC apoptosis. Serum starvation or treatment of human VSMCs with apoptosis inducers (STS or VP-16) significantly reduced
CREG
expression and caused
caspase-3
activation.
CREG
downregulation and
caspase-3
activation were inversely related, suggesting that reduced
CREG
expression may contribute to VSMC apoptosis. Both loss-of-function (
CREG
-DW produced by retroviruses expressing
CREG
shRNAs) and gain-of-function (
CREG
-UP produced by retroviral infection with vector pLNCX-
CREG
) studies were performed to confirm this hypothesis.
CREG
-DW significantly increased VSMC apoptosis, whereas
CREG
-UP significantly reduced apoptosis. Moreover, p38 and JNK mitogen-activated protein kinases were significantly upregulated in
CREG
-DW and significantly reduced in
CREG
-UP VSMCs. More importantly,
CREG
-DW-induced VSMC apoptosis was blocked by the p38-specific inhibitor SB203580 or by overexpression of a dominant-negative P38 alpha (p38 alpha AGF). Balloon injury-induced vascular
caspase-3
activation was significantly inhibited by treatment with recombinant
CREG
protein. These results demonstrated for the first time that
CREG
plays a key role in modulating VSMC apoptosis through the p38 and JNK signal transduction pathways, both in vitro and in situ.
...
PMID:Cellular repressor of E1A-stimulated genes inhibits human vascular smooth muscle cell apoptosis via blocking P38/JNK MAP kinase activation. 2006 3